Richard D. Finkelman is a Senior Director in Clinical Research AstraZeneca LP Clinical Pharmacology & DMPK Wilmington.

Jimmy Thomas Efird is a Visiting Associate Professor of Center for Health of Vulnerable Populations  at University of North Carolina, USA.

Yanming Wang is an Associate Professor of the Department of Radiology, Director of Radiopharmaceutical Division, Case Center for Imaging Research Case Western Reserve University Cleveland, USA.

Rajendra Sharma was a Research fellow, Rajasthan University, Jaipur, India (1975-1979). Synthesized 3,4:6,7-dibenzomorphans, the compounds related to 6,7- benzomorphans (potent analgesics). Evaluated pharmacological efficacy of substituted 3,4:6,7-dibenzomorphans Research Associate, All India Institute of Medical Sciences, New Delhi (1980-1981) Investigated the energetics of radiation induced DNA damage and its repair mechanisms in normal and cancer cells. Identified relationship between DNA repair and the rate of cellular energy supply. Post-doctoral fellow (1989-1991) Purified and characterized a novel membrane transport protein DNP-SG ATPase from human erythrocytes. Established involvement of DNP-SG ATPase in the transport of glutathione conjugates of electrophilic compounds in humantissues. Showed the expression of DNP-SG ATPase in different human tissues. Purified and characterized glutathione S-transferases from mammalian tissues. Suptdg. Chemist at KDMIPE, Dehradun, India ( April 1991- March 2000)Analyzed pollutants from the surrounding areas of oilfields of Indian sedimentary basins.Investigated the toxic impact of petroleum hydrocarbons on human tissues.Visiting Scientist at UTMB, Galveston, TX (April 2000-Sept. 2003) Stably transfected cultured cells (HLE B-3) with human glutathione S-transferase A4 gene and demonstrated role of 4-hydroxynonenal in cell cycle and apoptotic signaling.Purified and characterized recombinant human RLIP76 a non-ABC transport protein and demonstrated a major role of RLIP76 in the ATP-dependent transport of glutathione-conjugates and chemotherapeutic agents in human erythrocytes and cultured cells.Suptdg, Chemist at KDMIPE, Dehradun, India ( Oct 2003- Aug.2005): Team leader- Project entitled “DNA finger printing technique in oil exploration”.

Pavol Zubor is an Associate Professor of the Department of Obstetrics and Gynecology.

Gary Guishan Xiao is a Director of the Functional Genomics and Proteomics laboratories at the Creighton University Osteoporosis Research Center, is an internationally recognized expert in the field of proteomics and metabolomics of cancers and bone disease. Dr. Xiao earns his Ph.D. in molecular computational biology about a dozen years ago, focusing on structural modeling of ligand-enzyme interaction and prediction of protein refolding pathways during protein translational process. Dr. Xiao had his postdoctoral research trained in Baylor College of Medicine and UCLA, focusing on pharmacokinetics and biochemistry of non-steroid inflammatory drugs such as aspirin-derivatives and their target, human prostaglandin H synthases H1 and H2, and cell cycle regulation, especially, the role of c-Myc in cardiac termination differentiation. Dr. Xiao’s research at harbor UCLA medical Center and City of Hope National Cancer Center were highly focused on genomic and proteomic interpretations of diet-induced obesity/diabetes and its complications such cancers and osteoporosis. Dr. Xiao joined Osteoporosis Research Center at the Creighton University Medical Center since 2007. Dr. Xiao has been regular reviewer or ad hoc reviewer for several medial journals, different funding agency such as NIH and several journal Editorial Board members.

Sreenivasa R. Chinni is an Associate Professor in the Department of Urology and Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University, USA.

Yu-Fei Jiao is a Professor of the Department of Pathology, Hospital of Harbin Medical University, China.

Harvey I. Pass is a Phi Beta Kappa graduate of the Johns Hopkins University and Duke Medical School. After completing his cardiothoracic training at the Medical University of South Carolina and a year as a cardiac surgery attending physician, he devoted his career to treating thoracic malignancies including lung cancer, pulmonary metastases, esophageal cancer, and mesothelioma. Dr. Pass completed a 3-year senior fellowship in the Thoracic Oncology Surgical Branch of the National Cancer Institute (NCI). There, he was mentored by Dr. Jack Roth and Dr. Steven Rosenberg in developing novel clinical trials from laboratory investigations. Dr. Pass was appointed Head of Thoracic Oncology for NCI in 1986, and held this position for ten years. From 1996 to 2005, Dr. Pass built the thoracic oncology program at Karmanos Cancer Institute of Wayne State University. In 2005, Dr. Pass was recruited to be the first Director of the NYU Division of Thoracic Surgery. His laboratory at Bellevue Hospital is the home of the NCI-funded Early Detection Research Network Biomarker Discovery Laboratory for Mesothelioma, and the Clinical CORE for the NCI’s recently funded Mesothelioma Pathogenesis Program Project. He has solidified NYU’s 3-year Thoracic Fellowship Training Program for individuals interested in general thoracic surgery. The program trains superb surgeons and thoracic scientists for the future. Dr. Pass serves as an Ad Hoc reviewer for publications including New England Journal of Medicine, JAMA, International Journal of Cancer and Journal of Clinical Oncology. He is a vigorous advocate for patients with lung cancer and mesothelioma, serving as a Lung Cancer Alliance Board member, and Chairman of the Scientific Advisory Board for the Mesothelioma Applied Research Foundation. He has been awarded Castle Connolly’s Americas Top Doctors award for the last five years.

Samy L. Habib is an Assistant Professor of the Department of Medicine, The University of Texas, Health Science Center, San Antonio, TX, USA and has strong background in molecular carcinogenesis, with specific training and expertise in several research areas. He was a co-Investigator on several previous and current projects funded by ADA, NKF, AHA, VA and NIH. Attesting to his national visibility,he has been selected to serve as a regular reviewer for the Medical Research Program of the Department of Defense and Editorial Board Member of 2 Journals.

Arutselvan Natarajan is an Instructor, Molecular Imaging Program at Stanford, Department of Radiology, School of Medicine, Stanford University. Assistant Research Professor, Radiodiagnosis and Therapy Section, Internal Medicine, School of Medicine, University of California Davis (2005-2009). Advance Postdoctoral Fellow, Radiodiagnosis and Therapy Section, Internal Medicine, School of Medicine, University of California Davis (2002-2005). PhD in Industrial Chemistry at Alagappa University, India (2000). MS., in Pharmaceutical and Biochemistry (1990). B.Sc., in Chemistry in Madras University, India, NY (1982). Number of publications and book chapters 40, Conference Presentations: 60. Reviewer for peer reviewed scientific journals: Cancer Biotherapy and Radiopharmaceuticals, Bioconjugate Chemistry, Langmuir, ACS Nano and Molecules.

Sudhakar Akul Yakkanti is a Founder Director of Cell Signaling Tumor and Retinal Angiogenesis Laboratory, Boys Town National Research Hospital, Omaha, NE, USA. He is a Clinical Professor of Creighton University and Nebraska Medical Center. He did his postdoctoral training at Harvard Medical School Boston, USA (2003). He has received PhD (2001), M.Phill (1997) and MSc (1995) degrees in life sciences from University of Hyderabad and B.Sc in Biology from SK University (1993) from India. He was received President’s fellowship, GATE and CSIR fellowships from government of India. He received Mahindra & Mahindra Travel Award and YCS Award from FAMRI. He received Bio-Bio Young Scientist Award from OMICS and RO1 grant award from NIH/NCI. He is serving as AIBS/NIH-Grant reviewer. He has published more than 40 research articles including Science, JCI, Cancer Cell, PNAS, Blood etc. He is serving as an Editor-In Chief, Editor, Associate editor and Editorial board member of 13 reputed journals and serving as reviewer of 26 scientific journals.

Suresh Koduru is a Research Scientist at Children’s Hospital Boston, Harvard Medical School, Boston. He has received a PhD in Biochemistry from University of Hyderabad, Hyderabad, India. He has completed his M.S. in Biochemistry from S.V.University, Tirupathi, Inida. He received “Paul Doubler” award for excellence in studying Primary Immunodeficiency” in Human/Animal models. He has published 13 papers in peer-reviewed journals and he is serving as a member for Sigma Xi at Harvard Chapter.

Ratna K Vadlamudi received his doctorate in Molecular Biology from the University of Wyoming, Laramie, WY in 1994.  He completed his postdoctoral training at Harvard Medical School / Dana Farber Cancer Institute in 1997. His Academic appointments have included Assistant and Associate Professor in the Department of Molecular and Cellular Oncology, MD Anderson Cancer Center and Associate Professor, in the Department of Genetics, Stanley S. Cancer Center, LSUHSC New Orleans. Dr. Vadlamudi’s research has focused on understanding the molecular mechanism of Nuclear Receptor Signal transduction using Estrogen Receptor as a model system.

Pratap Kumar is an Associate Professor of the Department of Urology, The University of Texas Health Science Center at San Antonio, TX, USA. As a member of the Editorial Board, he assists in establishing editorial policy for the journal and in evaluating the material which has been submitted by others in the field of cancer science for publication in the journal. This will entail several peer reviews a year and responsibilities to select other expert to review articles. Dr Kumar was chosen as member of the Editorial Board on the basis of his expertise in the field of molecular cancer prevention especially exploiting natural products in conjunction with standard of care with special reference to Genitourinary and gastrointestinal malignancies.

Zhen Cheng is an Assistant Professor of Radiology and a member of the Molecular Imaging Program at Stanford (MIPS), BioX program, Canary Center at Stanford for Cancer Early Detection and Stanford Cancer Center. He received his PhD in Chemistry from the University of Missouri-Columbia and completed his post-doc at Harvard Medical School. Dr. Cheng has published over 60 peer reviewed articles. He has served as reviewers for several funding agencies including National Institute of Health (NIH), Department of Defense (DOD) and Department of Energy (DOE). He is also actively serving as a reviewer for over 30 journals and an editorial board member of three journals. Dr. Cheng received Young Investigator Award form Melanoma Research Alliance, New Instigator Award from DOD, and 2009 Best Basic Science Paper from Journal of Nuclear Medicine. Dr. Cheng is currently the head of the Cancer Molecular Imaging Chemistry Laboratory of MIPS where he is developing novel molecular imaging probes, non-invasive imaging techniques and bionanotechnology for the early detection and treatment of cancer.

Chulso Moon has a 1. Tenure Track Professorship in the Department of Oncology, Otolaryngology, Head and Neck Surgery, The Johns Hopkins University School of Medicine (2001-2007). 2. Principal Investigator, The Head and Neck Cancer Research Institute, The Johns Hopkins University School of Medicine (Director: Dr. David Sidransky) (2001-). 3. Attending physician, The Johns Hopkins Hospital (2001-2006). 4. Principal investigator, ONXY-015 cancer genetherapy program for advanced head/neck cancer (2001-2003). 5. Adjunct Professorship, Department of Otolaryngology and Head and Neck Surgery, The Johns Hopkins University school of Medicine (2008- Present). 6. Preceptor, Graduate Program in Human Genetics and Molecular Biology, The Johns Hopkins University school of Medicine (2005- Present, Thesis Advisor for Juna Lee, 2010 Ph.D. Candidate). 7. Director of Medical Oncology, Cleo Craig Memorial Cancer Clinic, The South-Western Medical Center, Lawton OK (2010-Present).

Jagat R Kanwar is an immunologist and molecular biochemist with an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. He did his PhD from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Before joining Deakin University in 2006, he was a Senior Scientist/Senior Research Fellow in the University of Auckland, Auckland, New Zealand. During the past decade his research both academic and commercial has centered on understanding the pathophysiological mechanisms and/or finding treatments for a variety of chronic inflammatory diseases and different types of cancer. Dr Kanwar has published 55 research articles, 12 invited reviews and 5 book chapters, in highly ranked, international, peer-reviewed journals. These publications have added to the body of knowledge in the fields of immunology, cancer gene therapy, nanomedicine, cell biology and biotechnology, and have extended these disciplines. He is a key inventor on 9 international patents and has provided consultancy to 5 Biotechnology based companies. He is a member of editorial board for 7 international journals and a nominated member of more than 12 national and international societies including American Society of Nanomedicine. He has extensive and close collaborations with colleagues from New Zealand, Australia, Singapore, India, China and USA.

Vincent Wilson is a Professor of Toxicology in the Department of Environmental Sciences, School of the Coast & Environment at Louisiana State University, Baton Rouge, Louisiana. He received his PhD in Pharmacology & Toxicology from Oregon State University in 1980 and proceeded to postdoctoral studies in molecular genetics under the direction of Dr. Peter A. Jones at the University of Southern California Comprehensive Cancer Center.  With a focus on chemical carcinogenesis, Vincent then spent five years at the National Cancer Institute, NIH, Bethesda, MD, in the Laboratory for Human Carcinogenesis, under the direction of Dr. Curt Harris.  The attraction of an offer to build, develop and run a laboratory for DNA diagnostics for clinical genetics and oncology services drew him out of NCI to The Children’s Hospital, Denver, CO, and the Department of Pathology, University of Colorado Health Sciences Center for six years before accepting a faculty position at the Louisiana State University in 1994.  He served as Chair, Interdepartmental Program in Toxicology at LSU for eleven years.